Navigation Links
Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
Date:9/24/2007

contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals, Inc. future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and Cethrin, the prospects of the Company's CNS therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals, Inc. from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres Pharmaceuticals, Inc. is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Contact:

Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-23
'/>"/>

SOURCE Alseres Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... LOS ANGELES , Sept. 19, 2014  CytRx ... and development company specializing in oncology, today announced that ... will present at BioCentury,s 2014 NewsMakers in the Biotech ... p.m. Eastern Time. The conference will take place at ... City . A live and archived ...
(Date:9/19/2014)... -- Reductions in kidney failure obtained during ... with diabetes type 2 "Intensive treatment is ... kidneys." Australian researchers have discovered that intensive ... to persistent reductions in kidney failure many years after ... has found that, five and a half years after ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
... Audax Medical, Inc. ( www.audaxmed.com ), a privately held ... has been awarded a research and development grant through ... was established under the Patient Protection and Affordable Care ... innovative, reduce long-term healthcare costs, and/or address unmet medical ...
... 2010 The American Heart Journal today ... lead product candidate, AMR-001 for the treatment of damaged ... a significant relationship between cell dose and biologic effect. ... define a dose of a purified and potent autologous ...
Cached Medicine Technology:Audax Medical, Inc. Receives Therapeutic Discovery Grant for Development of Regenerative Bone Material 2Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 2Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 3
(Date:9/20/2014)... (PRWEB) September 20, 2014 New ... and Market Analysis to 2023?. The asthma market ... as it has become saturated with relatively efficacious ... corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), ... increasing generic competition. However, the launch of seven ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a ... website. The new site provides the latest reviews ... customers. Here, people can find a lot of ... it has recommended some excellent web hosting suppliers ... great web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), ...
(Date:9/20/2014)... September 20, 2014 "As a nurse, patients ... tanks," said an inventor from Tamaqua, Pa. "The reason that ... the backs of their chairs. My invention enables them to ... Kam Oxygen Sensor to make it easier to monitor the ... user knows when the tank is low. It allows changeovers ...
(Date:9/20/2014)... Earlier this week, Home Depot revealed that up to ... card information pilfered by hackers, surpassing the 40 million Target ... articles like this one published by Bloomberg on September ... , “Most people tend to focus on how many credit ... score a game,” says Joe Caruso, founder and CEO/CTO of ...
(Date:9/20/2014)... September 20, 2014 Final Cut Pro ... the release of the Information theme for FCPX filmmakers. , ... to describe the Information theme,” says Christina Austin, CEO of ... look so professional.” , Information features easy to use controls ... of the environment. Change the background color, color of each ...
Breaking Medicine News(10 mins):Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2
... to the latest on breast-feeding, there is no hard and ... newborn. Most young mothers would be more// than glad ... while breast feeding, can prove too painful for motherly feelings ... Adolphe. Nicola accordingly, had a horrendous time trying to breastfeed ...
... prince donates his youth to his father so that he could ... is at hand now. For scientists say they have discovered a ... by manipulating that gene perhaps one could live longer, they hope. ... lifespan of animals that are subjected to a calorie-restricted diet -when ...
... Anti-depressants could indeed lift one out of depression. But ... been recognized//. ,Now the U.S. Food and ... antidepressant medications update the existing black box warning on ... of suicidal thinking and behavior, in young adults ages ...
... pregnancy, migraine and stroke, US researchers said. The combination ... fact, Cheryl Bushnell, assistant professor of neurology at the ... that pregnant women who suffered migraine carried a risk ... did not suffer migraine. ,Elaborating on the ...
... know that older women - those 80 or older - have ... published today. ,Worryingly, the research also found that 56 ... breast cancer risk. ,The strongest risk factor for breast ... higher her risk. About one in 70 women will develop breast ...
... of moderate to severe chronic obstructive pulmonary disease//, or ... ,The results of the randomized, double-blind, placebo-controlled trial of ... May American Journal of Respiratory and Critical Care Medicine, ... to an editorial commenting on the research, the failure ...
Cached Medicine News:Health News:New Research Promises To Take The Pain Off Breast Feeding 2Health News:New Research Promises To Take The Pain Off Breast Feeding 3Health News:Gene Responsible for Ageing Process Discovered – and Calorie Restriction Could Hel 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3Health News:Women Unaware of When Breast Cancer Risk is Greatest 2Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: